This second generation siRNA set from Qiagen enables gene silencing studies of 6992 potential human druggable targets
Qiagen announces delivery of its new Human Druggable Genome siRNA set V2.0 to the Scripps Research Institute in Florida.
This second generation siRNA set from Qiagen enables gene silencing studies of 6992 potential human druggable targets.
siRNAs are designed using the innovative HiPerformance siRNA design algorithm, ensuring maximum silencing and minimum risk of nonspecific effects.
"We selected the siRNA set from Qiagen based on our criteria for siRNA design specificity, expertise in high-throughput siRNA synthesis, and dedicated support", John Hogenesch, director of genome technology, said.
"Biology in the post-genomic era is marked by the desire to study cells, cellular processes, and disease at a genome-wide level.
"The genome technology group at Scripps Florida aims to leverage these high-throughput tools and technologies toward a systematic description of genes encoded by the human genome, and a more comprehensive understanding of the genetic basis for human disease".
Scripps Florida researchers will use the siRNAs in combination with an assortment of high-throughput phenotypic screening technologies to interrogate novel mammalian gene function in cell based assays.
"We are delighted that the Scripps Research Institute selected our Human Druggable Genome siRNA Set," commented Jie Kang, VP R and D at Qiagen.
"Scripps joins a long list of other pharmaceutical and academic research centres in applying high-throughput RNAi applications with our products and dedicated support.
"We look forward to more exciting discoveries and publications in this regard".
The Scripps Research Institute, headquartered in La Jolla, California, is one of the world's largest independent, non-profit biomedical research organisations.
It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life.
Scripps Research is internationally recognised for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development.
Established in its current configuration in 1961, it employs approximately 3000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel.
Scripps Florida, a state-of-the-art biomedical research facility, is under construction in Palm Beach County.
The facility will focus on basic biomedical science, drug discovery, and the application of the latest research technologies.
Palm Beach County and the State of Florida have provided start-up economic packages for development, building, staffing, and equipping the campus.
Scripps Florida now operates with approximately 150 scientists, technicians, and administrative staff at lab facilities on the Florida Atlantic University campus in Jupiter.
Qiagen, a Netherlands holding company with subsidiaries in Germany, the United States, China, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins.
Qiagen has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services.
Qiagen's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies.
In addition, Qiagen is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy.
Qiagen employs more than 1500 people worldwide.
